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Conclusion:Vulvovaginal atrophy is a common disorder in menopausal women, however 
vulvovaginal atrophy (VVA) is an underreported condition associated with decreased estrogenization 
of the vaginal tissue. The knowledge and awareness of current aspects of its diagnosis, treatment and 
prevention will be able to render timely aid to patients and to improve their quality of life. 
After using the above methods of diagnosis and treatment, it can be said that the use of hormonal 
therapy and laser therapy is effective and can be used on women of all ages.  
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The fertility of a couple depends upon several factors in both the male and female. Ovulation 
induction involves the use of medication to stimulate development of one or more mature follicles in 
the ovaries of women who have anovulation and infertility. Letrozole, an aromatase inhibitor, has 
been demonstrated to be effective as an ovulation induction and controlled ovarian hyperstimulation 
agent.  
Introduction. The drug works primarily by competitively inhibiting the binding of estradiol to 
its receptor in the hypothalamus, thereby releasing the hypothalamus from negative inhibition and 
allowing increased release of follicle stimulating hormonefrom the pituitary. 
Letrozolehad been used in anovulatory women with great success. The drug has side effects far 
milder and less frequentthan others. 
Materials and Methods. This study is a retrospective cohort analysis with data extracted from 
medical record. Logistic regression analysis were performed to determine the importance of each 
predictor variable and its covariates. Terms remained in the equation as significant if 𝑃<0.15. 
Results. A total of 866 treatment cycles utilized a five-day dose of letrozole. 33 were 
administered 5 mg daily, 80 - 7.5 mg daily, 18 - 10 mg daily, and 735-12.5 mg daily. The number of 
predicted ovulations was significantly less for doses of 7.5 mg/day or less compared to doses of 
10 mg/day or more (𝑃< 0.001). This remained true when the data were filtered to include only first 
cycles on a given dose (𝑃 = 0.033). No significant differences were seen for pregnancy rates among 
doses. 
Summary. Letrozole, used in doses greater than those commonly employed, can produce 
enhanced follicular growth without detrimental effects upon the endometrium. Further study is clearly 
needed, including estradiol and androgen levels. Randomized trials comparing high-dose to low-dose 
administration would help determine the optimal starting dose for this medication in varying 
diagnoses. 
  
